The Board of Directors and the Managing Director of Dextech Medical AB (DexTech), org.no. 556664-6203, with its registered office in Stockholm, may hereby submit the annual report for the financial year 2018-07-01 - 2019-06-30.

For further information:

Gösta Lundgren - CFO & Investor Relations

DexTech Medical AB

Phone: +46 (0) 707104788

E-mail: gosta.lundgren@dextechmedical.com

The information was submitted for publication on September 19, 2019, through the above contact persons.

DexTech Medical AB is a Swedish research company that, based on its technology platform, has developed four drug candidates that are protected by patents. The main candidate is OsteoDex for the treatment of castration-resistant prostate cancer (CRPC) with skeletal metastases. A successful Phase II clinical study has been conducted with OsteoDex where the result shows high tolerability with mild side effects as well as efficacy and treatment effect on patients who fail on existing drugs. DexTech"s goal is to license the respective drug candidate by the latest phase II study. DexTech Medical AB is listed on the Spotlight Stock Market.